THE IMPACT OF PHARMACEUTICAL CARE ON IMPROVING THE QUALITY OF LIFE IN PATIENTS WITH ALLERGIC RHINITIS
Introduction: Allergic rhinitis (AR) is a chronic disease with great social and economic impact that is largely undiagnosed and inadequately self-treated. Healthcare professionals such as pharmacists play a key role in recognizing and assessing the severity of AR, dispensing of OTC drugs, counseling of patients and in severe cases, referring them to health care specialists for further treatment.
Objective: This study explores the impact of pharmaceutical care and patient counseling on the self-management of seasonal AR.
Methods: The participating pharmacists follow the stepwise algorithm of ARIA (Allergic Rhinitis and its Impact on Asthma) Pharmacist’s Guide. The effectiveness of the specialized pharmaceutical care is assessed by the changes in patients’ quality of life (QOL) before and after the provision of patient counseling and pharmacist monitoring on patient self-management. The quality of life is measured with the help of the generic tool 12v2 SF.
Results: As a result of the provided pharmaceutical care, the analysis indicates improvement of all assessed aspects of patients’ QOL. The analysis shows that the better scores of the indicators Physical functioning, Vitality, Physical health and Mental health are not accidental; rather, they are in a statistically significant correlation with the provided pharmaceutical care.
Conclusion: The study highlights the need for professional patient counseling and the education of patients to perform adequate disease management and improve their quality of life.
Allergic Rhinitis and Its Impact on Asthma (ARIA) http://www.whiar.com
Allergies in America. A telephone survey conducted in 2500 adults with allergic rhinitis. Health star communications. Inc., in partnership with Shulman, Ronca and Bucuvalas, Inc. Allergies in America: A landmark survey on nasal allergy sufferers. Executive summary. 2006.
ARIA Pocket Guide for Pharmacists. In Edition 2003.
Baiardini I, Braido F, Brandi S, Canonica GW. Allergic diseases and their impact on quality of life. Ann Allergy Asthma Immunol. 2006; 97:419–428;
Bousquet J, Khaltaev N, Cruz A, et al. Allergic rhinitis and its impact on asthma update. Allergy 2008; 63Supl 86: 9 – 160.
Bousquet J, van Cauwenberge P, Khaltaev N. Allergic rhinitis and its impact on asthma (ARIA)- Executive summary. Allergy 2003;57:841–855
Brozek JL, Bousquet J, Baena-Cagnani CE et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 revision. J Allergy Clin Immunol 2010; 126: 466-476.
Camelo-Nunes IC, Sole D. Allergic rhinitis: indicators of quality of life. J Bras Pneumol 2010; 36(1); 124 – 33.
Canonica GW, Bousquet J, Mullol J et al. A survey of the burden of allergic rhinitis in Europe. Allergy 2007; 62 Suppl 85: 17-25
Cuel B, Wamboldt M, Borish L. et al. Economic consequences of comorbid depression, anxiety and allergic rhinitis. Psychosomatics, 1999; 40: 491 – 496.
Dessing RP. Ethics applied to pharmacy practice. Pharm World Sci 2000; 22: 10–16
Guidelines on Good Pharmacy Practice, Approved by the Minister of Health ref.No 62-00-70-08/11.03.2009
Meltzer EO, Gross GN, Katial R, Storms WW. Allergic rhinitis substantially impacts patient quality of life: findings from the Nasal Allergy Survey Assessing Limitations. J Fam Pract. 2012;61(2):5-10.
Pawankar R, Canonica G, Holgate S, Lockey R. WAO White Book on Allergy 2011-2012. In Edition Milwakee, Wisconsin, USA: WAO 2011.
Todorova A., Tsvetkova A., Arnaoudova M., Dimitrov M., Researching the quality of life in patients with seasonal allergic rhinitis practicing self- treatment, WJPPS, 2015, 4 (12):1-11
Tsvetkova A., Todorova A., Tsvetkov L., Mihailova S., Dimitrov M., The role of the pharmacist in achieving therapeutic efficacy and cost effectiveness in the management of allergic rhinitis” International Journal of Information Research and Review 2015; 2(4). 593-596,
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License (Creative Commons Attribution License 3.0 - CC BY 3.0) that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
email@example.com, www.iseic.cz, ojs.journals.cz